Literature DB >> 19276238

Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose.

Samuel Dagogo-Jack1, Hasan Askari, Gunjan Tykodi.   

Abstract

OBJECTIVE: We determined whether variations in fasting plasma glucose (FPG) within the nondiabetic range represent differences in insulin action or secretion. SUBJECTS AND METHODS: Using results of the 75-g oral glucose tolerance test, we classified 39 adults (body mass index range 20-56 kg/m2) as having normal fasting glucose (NFG, <100 mg/dl, n = 24) or impaired fasting glucose (IFG, 100-125 mg/dl, n = 15). The NFG group was subdivided into low-NFG (<90 mg/dl, n = 11) and high-NFG (90-99 mg/dl, n = 13). The 2-h oral glucose tolerance test plasma glucose value was used to assign normal or impaired glucose tolerance (IGT) status. Insulin sensitivity was assessed by hyperinsulinemic euglycemic clamp, quantitative insulin sensitivity check index, and homeostasis model assessment of insulin resistance; beta-cell function was assessed by calculating the insulinogenic index, homeostasis model assessment, and the disposition index.
RESULTS: Compared with low-NFG subjects, insulin sensitivity and glucose tolerance were lower among persons with isolated IFG and combined IFG-IGT. The hyperinsulinemic euglycemic clamp (micromol/kg x min(-1)/pmol/liter) was 0.109 +/- 0.011 in low-NFG subjects, 0.088 +/- 0.009 in IFG subjects (P = 0.04), and 0.022 +/- 0.003 in IFG-IGT subjects (P = 0.0014). The spread in FPG from 70-125 mg/dl was associated with a greater than 3-fold difference in insulin sensitivity. Compared with low-NFG subjects, the disposition index decreased by 32.8% in high-NFG subjects (P = 0.08), by 45.6% in subjects with isolated IFG (P < 0.02), and by 49.8% (P < 0.02) in those with combined IFG-IGT.
CONCLUSION: Compared with persons with low-NFG, those with IFG or combined IFG-IGT have significant alteration of glucoregulatory physiology, whereas high-NFG (pre-prediabetes) status might portend nascent glucoregulatory perturbations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276238      PMCID: PMC2690430          DOI: 10.1210/jc.2008-1348

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Glucose intolerance is predicted by the high Fasting Insulin-to-Glucose ratio.

Authors:  F Guerrero-Romero; M Rodríguez-Morán
Journal:  Diabetes Metab       Date:  2001-04       Impact factor: 6.041

Review 2.  Follow-up report on the diagnosis of diabetes mellitus.

Authors:  Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

3.  Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic?

Authors:  David L Schriger; Brett Lorber
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

Review 4.  Prediabetes: prediction and prevention trials.

Authors:  Francesco Vendrame; Peter A Gottlieb
Journal:  Endocrinol Metab Clin North Am       Date:  2004-03       Impact factor: 4.741

5.  Indices of insulin action, disposal, and secretion derived from fasting samples and clamps in normal glucose-tolerant black and white children.

Authors:  Gabriel I Uwaifo; Erica M Fallon; Jeff Chin; Jane Elberg; Shamik J Parikh; Jack A Yanovski
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

6.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

Authors:  E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

7.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

8.  Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity.

Authors:  Devjit Tripathy; Peter Almgren; Tiinamaija Tuomi; Leif Groop
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

9.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Authors:  Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

View more
  15 in total

Review 1.  Prediabetes and Cardiovascular Disease: Pathophysiology and Interventions for Prevention and Risk Reduction.

Authors:  Ben Brannick; Sam Dagogo-Jack
Journal:  Endocrinol Metab Clin North Am       Date:  2018-03       Impact factor: 4.741

Review 2.  Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk.

Authors:  Samuel Dagogo-Jack; Nonso Egbuonu; Chimaroke Edeoga
Journal:  Med Princ Pract       Date:  2010-03-29       Impact factor: 1.927

3.  Fasting plasma leptin level is a surrogate measure of insulin sensitivity.

Authors:  Hasan Askari; Gunjan Tykodi; Jianmei Liu; Samuel Dagogo-Jack
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

4.  High normal fasting glucose level in obese youth: a marker for insulin resistance and beta cell dysregulation.

Authors:  G O'Malley; N Santoro; V Northrup; E D'Adamo; M Shaw; S Eldrich; S Caprio
Journal:  Diabetologia       Date:  2010-03-05       Impact factor: 10.122

Review 5.  Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.

Authors:  Ben Brannick; Anne Wynn; Samuel Dagogo-Jack
Journal:  Exp Biol Med (Maywood)       Date:  2016-06

6.  Metabolomic prediction of diabetes and cardiovascular risk.

Authors:  Samuel Dagogo-Jack
Journal:  Med Princ Pract       Date:  2012-06-15       Impact factor: 1.927

Review 7.  Prediabetes as a therapeutic target.

Authors:  Omid Rad Pour; Samuel Dagogo-Jack
Journal:  Clin Chem       Date:  2010-11-09       Impact factor: 8.327

8.  Glucoregulatory function among African Americans and European Americans with normal or pre-diabetic hemoglobin A1c levels.

Authors:  Sotonte Ebenibo; Chimaroke Edeoga; Jim Wan; Samuel Dagogo-Jack
Journal:  Metabolism       Date:  2014-03-05       Impact factor: 8.694

9.  Normal fasting plasma glucose and risk of type 2 diabetes.

Authors:  Paolo Brambilla; Elisa La Valle; Rosanna Falbo; Giuseppe Limonta; Stefano Signorini; Fabrizio Cappellini; Paolo Mocarelli
Journal:  Diabetes Care       Date:  2011-04-15       Impact factor: 19.112

10.  Determinants of impaired fasting glucose versus glucose intolerance in polycystic ovary syndrome.

Authors:  Sidika E Karakas; Kyoungmi Kim; Antoni J Duleba
Journal:  Diabetes Care       Date:  2010-01-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.